165 related articles for article (PubMed ID: 16911813)
1. The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome.
Filippatos TD; Gazi IF; Liberopoulos EN; Athyros VG; Elisaf MS; Tselepis AD; Kiortsis DN
Atherosclerosis; 2007 Aug; 193(2):428-37. PubMed ID: 16911813
[TBL] [Abstract][Full Text] [Related]
2. The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia.
Nakou ES; Filippatos TD; Georgoula M; Kiortsis DN; Tselepis AD; Mikhailidis DP; Elisaf MS
Curr Med Res Opin; 2008 Jul; 24(7):1919-29. PubMed ID: 18513463
[TBL] [Abstract][Full Text] [Related]
3. Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study.
Filippatos TD; Kiortsis DN; Liberopoulos EN; Georgoula M; Mikhailidis DP; Elisaf MS
Curr Med Res Opin; 2005 Dec; 21(12):1997-2006. PubMed ID: 16368051
[TBL] [Abstract][Full Text] [Related]
4. The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome.
Filippatos TD; Liberopoulos EN; Kostapanos M; Gazi IF; Papavasiliou EC; Kiortsis DN; Tselepis AD; Elisaf MS
Diabetes Obes Metab; 2008 Jun; 10(6):476-83. PubMed ID: 17459096
[TBL] [Abstract][Full Text] [Related]
5. Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial.
Kei A; Liberopoulos E; Tellis K; Rizzo M; Elisaf M; Tselepis A
Eur J Clin Invest; 2013 Jul; 43(7):698-707. PubMed ID: 23600368
[TBL] [Abstract][Full Text] [Related]
6. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study.
Muls E; Kolanowski J; Scheen A; Van Gaal L;
Int J Obes Relat Metab Disord; 2001 Nov; 25(11):1713-21. PubMed ID: 11753595
[TBL] [Abstract][Full Text] [Related]
7. The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia.
Agouridis AP; Tsimihodimos V; Filippatos TD; Dimitriou AA; Tellis CC; Elisaf MS; Mikhailidis DP; Tselepis AD
Expert Opin Pharmacother; 2011 Dec; 12(17):2605-11. PubMed ID: 21714585
[TBL] [Abstract][Full Text] [Related]
8. Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome.
Rosenson RS
Am Heart J; 2008 Mar; 155(3):499.e9-16. PubMed ID: 18294485
[TBL] [Abstract][Full Text] [Related]
9. Effects of a low-calorie diet associated with weight loss on lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in healthy obese women.
Tzotzas T; Filippatos TD; Triantos A; Bruckert E; Tselepis AD; Kiortsis DN
Nutr Metab Cardiovasc Dis; 2008 Sep; 18(7):477-82. PubMed ID: 17928209
[TBL] [Abstract][Full Text] [Related]
10. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2.
Saougos VG; Tambaki AP; Kalogirou M; Kostapanos M; Gazi IF; Wolfert RL; Elisaf M; Tselepis AD
Arterioscler Thromb Vasc Biol; 2007 Oct; 27(10):2236-43. PubMed ID: 17656665
[TBL] [Abstract][Full Text] [Related]
11. The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia.
Nakou ES; Filippatos TD; Kiortsis DN; Derdemezis CS; Tselepis AD; Mikhailidis DP; Elisaf MS
Expert Opin Pharmacother; 2008 Dec; 9(18):3151-8. PubMed ID: 19040336
[TBL] [Abstract][Full Text] [Related]
12. Effect of orlistat on cardiovascular disease risk in obese adults.
Swinburn BA; Carey D; Hills AP; Hooper M; Marks S; Proietto J; Strauss BJ; Sullivan D; Welborn TA; Caterson ID
Diabetes Obes Metab; 2005 May; 7(3):254-62. PubMed ID: 15811142
[TBL] [Abstract][Full Text] [Related]
13. Short-term administration of orlistat reduced daytime triglyceridemia in obese women with the metabolic syndrome.
Tzotzas T; Samara M; Constantinidis T; Tziomalos K; Krassas G
Angiology; 2007; 58(1):26-33. PubMed ID: 17351155
[TBL] [Abstract][Full Text] [Related]
14. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study.
Muhlestein JB; May HT; Jensen JR; Horne BD; Lanman RB; Lavasani F; Wolfert RL; Pearson RR; Yannicelli HD; Anderson JL
J Am Coll Cardiol; 2006 Jul; 48(2):396-401. PubMed ID: 16843192
[TBL] [Abstract][Full Text] [Related]
15. Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome.
Agouridis AP; Kostapanos MS; Tsimihodimos V; Kostara C; Mikhailidis DP; Bairaktari ET; Tselepis AD; Elisaf MS
Int J Clin Pract; 2012 Sep; 66(9):843-53. PubMed ID: 22897461
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial.
Robins SJ; Collins D; Nelson JJ; Bloomfield HE; Asztalos BF
Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1172-8. PubMed ID: 18356553
[TBL] [Abstract][Full Text] [Related]
17. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study.
Athyros VG; Mikhailidis DP; Didangelos TP; Giouleme OI; Liberopoulos EN; Karagiannis A; Kakafika AI; Tziomalos K; Burroughs AK; Elisaf MS
Curr Med Res Opin; 2006 May; 22(5):873-83. PubMed ID: 16709309
[TBL] [Abstract][Full Text] [Related]
18. Simvastatin but not bezafibrate decreases plasma lipoprotein-associated phospholipase A₂ mass in type 2 diabetes mellitus: relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity.
Constantinides A; de Vries R; van Leeuwen JJ; Gautier T; van Pelt LJ; Tselepis AD; Lagrost L; Dullaart RP
Eur J Intern Med; 2012 Oct; 23(7):633-8. PubMed ID: 22902096
[TBL] [Abstract][Full Text] [Related]
19. The role of lipoprotein-associated phospholipase A(2) in the metabolic syndrome and diabetes.
Noto H; Chitkara P; Raskin P
J Diabetes Complications; 2006; 20(6):343-8. PubMed ID: 17070436
[TBL] [Abstract][Full Text] [Related]
20. Combining rosuvastatin with sartans of different peroxisome proliferator-activated receptor-γ activating capacity is not associated with different changes in low-density lipoprotein subfractions and plasma lipoprotein-associated phospholipase A₂.
Rizos CV; Liberopoulos EN; Tellis CC; Florentin M; Elisaf MS; Tselepis AD
Metab Syndr Relat Disord; 2011 Jun; 9(3):217-23. PubMed ID: 21352079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
